“Supporting care in diabetes, obesity and associated long-term conditions”
Since its creation in 2004, the PCDO Society has built a large membership of healthcare professionals working in primary care diabetes, run numerous highly successful educational conferences, played a role in the development of various toolkits and other healthcare initiatives, and worked in liaison with other professional groups and in lobbying politicians.
PCDO Society Committee posts are elected on a 3-yearly basis, with the cycles staggered across the representatives. The Committee is always interested to hear from Society members who are seeking to take a more active role, and one way in which this can be achieved is via membership of the Committee. Elected members generously give their own time. Much of the work is done by email, but there are typically four Committee meetings each year, usually held on Saturdays in Birmingham with preparatory meetings on the Friday evening.
This year, we are particularly seeking applications from the nursing profession.
How to stand for election to the PCDO Society Committee
To stand for election, please submit a resumé of up to 150 words to [email protected], along with a recent photograph, both of which will be published in Diabetes & Primary Care in the list of candidates. Please also note the following points:
- You must have a substantive NHS post working in the professional care of people with diabetes or obesity in a primary care setting.
- You must be a current member of the PCDO Society.
- The deadline for submitting your resumé is Friday 10th October.
- The Committee’s constitution seeks to ensure a balance between clinicians from medicine, nursing and allied professions, and also some geographical balance.
Voting will take place, and results announced, at the 21st National Conference of the PCDO Society, which is being held on 19–20 November 2025. Click on the image below for more information on this event.

It is crucial that we review retinal screening reports prior to prescribing GLP-1 or GIP/GLP-1 receptor agonists.
6 Aug 2025